Novel TAZ modulators enhance myogenic differentiation and muscle regeneration

British Journal of Pharmacology

Volumn 171, Issue 17, 2014, Pages 4051-4061

  Park, Gun Hwa ^a   Jeong, Hana ^a   Jeong, Mi Gyeong ^a   Jang, Eun Jung ^a   Bae, Myung Ae ^b   Lee, Ye Lim ^b   Kim, Nak Jung ^b   Hong, Jeong Ho ^c   Hwang, Eun Sook ^a  

^a Ewha Womans University   (South Korea)

^b Korea Research Institute of Chemical Technology   (South Korea)

^c Korea University   (South Korea)

Author keywords

muscle injury; muscle regeneration; MyoD; myogenic differentiation; TAZ modulators

Indexed keywords

2 BUTYL 5 STYRYL 1 [2' (1H TETRAZOL 5 YL)BIPHENYL 4 YLMETHYL] 1H BENZOIMIDAZOLE 6 CARBOXYLIC ACID METHYL ESTER; 2 BUTYL 6 STYRYL 1 [2' (1H TETRAZOL 5 YL)BIPHENYL 4 YLMETHYL] 1H BENZOIMIDAZOLE 5 CARBOXYLIC ACID METHYL ESTER; GREEN FLUORESCENT PROTEIN; IMIDAZOLE DERIVATIVE; MYOD PROTEIN; PROTEIN TAZ; SERINE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; 2-BUTYL-5-STYRYL-1-(2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YLMETHYL)-1H-BENZOIMIDAZOLE-6-CARBOXYLIC ACID METHYL ESTER; 2-BUTYL-6-STYRYL-1-(2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YLMETHYL)-1H-BENZOIMIDAZOLE-5-CARBOXYLIC ACID METHYL ESTER; BENZIMIDAZOLE DERIVATIVE; MYOGENIN; TETRAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL NUCLEUS; CELL TRANSDIFFERENTIATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ISOLATION; DRUG RESPONSE; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; EMBRYO; FIBROBLAST; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MUSCLE CELL; MUSCLE DEVELOPMENT; MUSCLE REGENERATION; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SCIATIC NERVE INJURY; ANIMAL; CELL LINE; CHEMISTRY; CHLOROCEBUS AETHIOPS; COS 1 CELL LINE; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; REGENERATION; SKELETAL MUSCLE; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; BENZIMIDAZOLES; CELL DIFFERENTIATION; CELL LINE; CERCOPITHECUS AETHIOPS; COS CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; MICE; MUSCLE, SKELETAL; MYOBLASTS; MYOGENIN; REGENERATION; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAZOLES;

EID: 84905993413     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12755     Document Type: Article

References (33)

1. Abbadie C, Lindia JA, Cumiskey AM, Peterson LB, Mudgett JS, Bayne EK, et-al. (2003). Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2. Proc Natl Acad Sci U S A 100: 7947-7952.
2. Arnold HH, Winter B, (1998). Muscle differentiation: more complexity to the network of myogenic regulators. Curr Opin Genet Dev 8: 539-544.
3. Berkes CA, Tapscott SJ, (2005). MyoD and the transcriptional control of myogenesis. Semin Cell Dev Biol 16: 585-595.
4. Bonaldo P, Sandri M, (2013). Cellular and molecular mechanisms of muscle atrophy. Dis Model Mech 6: 25-39.
5. Bonetto A, Penna F, Muscaritoli M, Minero VG, Rossi Fanelli F, Baccino FM, et-al. (2009). Are antioxidants useful for treating skeletal muscle atrophy? Free Radic Biol Med 47: 906-916.
6. Cui CB, Cooper LF, Yang X, Karsenty G, Aukhil I, (2003). Transcriptional coactivation of bone-specific transcription factor Cbfa1 by TAZ. Mol Cell Biol 23: 1004-1013.
7. Glass DJ, (2003). Signalling pathways that mediate skeletal muscle hypertrophy and atrophy. Nat Cell Biol 5: 87-90.
8. Glass DJ, (2005). Skeletal muscle hypertrophy and atrophy signaling pathways. Int J Biochem Cell Biol 37: 1974-1984.
9. Hong JH, Yaffe MB, (2006). TAZ: a beta-catenin-like molecule that regulates mesenchymal stem cell differentiation. Cell Cycle 5: 176-179.
10. Hong JH, Hwang ES, McManus MT, Amsterdam A, Tian Y, Kalmukova R, et-al. (2005). TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science 309: 1074-1078.
11. Hong W, Guan KL, (2012). The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol 23: 785-793.
12. Jang EJ, Jeong H, Han KH, Kwon HM, Hong JH, Hwang ES, (2012a). TAZ suppresses NFAT5 activity through tyrosine phosphorylation. Mol Cell Biol 32: 4925-4932.
13. Jang EJ, Jeong H, Kang JO, Kim NJ, Kim MS, Choi SH, et-al. (2012b). TM-25659 enhances osteogenic differentiation and suppresses adipogenic differentiation by modulating the transcriptional co-activator TAZ. Br J Pharmacol 165: 1584-1594.
14. Jankowski RJ, Deasy BM, Cao B, Gates C, Huard J, (2002). The role of CD34 expression and cellular fusion in the regeneration capacity of myogenic progenitor cells. J Cell Sci 115: 4361-4374.
15. Jeong H, Bae S, An SY, Byun MR, Hwang JH, Yaffe MB, et-al. (2010). TAZ as a novel enhancer of MyoD-mediated myogenic differentiation. FASEB J 24: 3310-3320.
16. Kanai F, Marignani PA, Sarbassova D, Yagi R, Hall RA, Donowitz M, et-al. (2000). TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J 19: 6778-6791.
17. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
18. Kumar A, Bhatnagar S, Paul PK, (2012). TWEAK and TRAF6 regulate skeletal muscle atrophy. Curr Opin Clin Nutr Metab Care 15: 233-239.
19. Lassar AB, Skapek SX, Novitch B, (1994). Regulatory mechanisms that coordinate skeletal muscle differentiation and cell cycle withdrawal. Curr Opin Cell Biol 6: 788-794.
20. Le Grand F, Rudnicki MA, (2007). Skeletal muscle satellite cells and adult myogenesis. Curr Opin Cell Biol 19: 628-633.
21. Lei QY, Zhang H, Zhao B, Zha ZY, Bai F, Pei XH, et-al. (2008). TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol 28: 2426-2436.
22. Liu CY, Lv X, Li T, Xu Y, Zhou X, Zhao S, et-al. (2011). PP1 cooperates with ASPP2 to dephosphorylate and activate TAZ. J Biol Chem 286: 5558-5566.
23. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
24. Muller FL, Song W, Jang YC, Liu Y, Sabia M, Richardson A, et-al. (2007). Denervation-induced skeletal muscle atrophy is associated with increased mitochondrial ROS production. Am J Physiol Regul Integr Comp Physiol 293: R1159-R1168.
25. Murton AJ, Constantin D, Greenhaff PL, (2008). The involvement of the ubiquitin proteasome system in human skeletal muscle remodelling and atrophy. Biochim Biophys Acta 1782: 730-743.
26. Muscaritoli M, Lucia S, Molfino A, Cederholm T, Rossi Fanelli F, (2013). Muscle atrophy in aging and chronic diseases: is it sarcopenia or cachexia? Intern Emerg Med 8: 553-560.
27. Olson EN, (1992). Interplay between proliferation and differentiation within the myogenic lineage. Dev Biol 154: 261-272.
28. Perry RL, Rudnick MA, (2000). Molecular mechanisms regulating myogenic determination and differentiation. Front Biosci 5: D750-D767.
29. Sabourin LA, Girgis-Gabardo A, Seale P, Asakura A, Rudnicki MA, (1999). Reduced differentiation potential of primary MyoD-/- myogenic cells derived from adult skeletal muscle. J Cell Biol 144: 631-643.
30. Tidball JG, (2005). Inflammatory processes in muscle injury and repair. Am J Physiol Regul Integr Comp Physiol 288: R345-R353.
31. Wang Y, Pessin JE, (2013). Mechanisms for fiber-type specificity of skeletal muscle atrophy. Curr Opin Clin Nutr Metab Care 16: 243-250.
32. Wolfe RR, (2006). The underappreciated role of muscle in health and disease. Am J Clin Nutr 84: 475-482.
33. Workeneh BT, Mitch WE, (2010). Review of muscle wasting associated with chronic kidney disease. Am J Clin Nutr 91: 1128S-1132S.